Literature DB >> 27859771

Engineering a gene silencing viral construct that targets the cat hypothalamus to induce permanent sterility: An update.

G A Dissen1, K Adachi2, A Lomniczi1, T Chatkupt3, B L Davidson4, H Nakai1,2, S R Ojeda1.   

Abstract

The intent of this contribution is to provide an update of the progress we have made towards developing a method/treatment to permanently sterilize cats. Our approach employs two complementary methodologies: RNA interference (RNAi) to silence genes involved in the central control of reproduction and a virus-based gene therapy system intended to deliver RNAi selectively to the hypothalamus (where these genes are expressed) via the systemic administration of modified viruses. We selected the hypothalamus because it contains neurons expressing Kiss1 and Tac3, two genes essential for reproduction and fertility. We chose the non-pathogenic adeno-associated virus (AAV) as a vector whose tropism could be modified to target the hypothalamus. The issues that must be overcome to utilize this vector as a delivery vehicle to induce sterility include modification of the wild-type AAV to target the hypothalamic region of the brain with a simultaneous reduction in targeting of peripheral tissues and non-hypothalamic brain regions, identification of RNAi targets that will effectively reduce the expression of Kiss1 and Tac3 without off-target effects, and determination if neutralizing antibodies to the AAV serotype of choice are present in cats. Successful resolution of these issues will pave the way for the development of a powerful tool to induce the permanent sterility in cats.
© 2016 Blackwell Verlag GmbH.

Entities:  

Keywords:  RNA interference; adeno-associated virus; microRNA

Mesh:

Substances:

Year:  2016        PMID: 27859771      PMCID: PMC5791761          DOI: 10.1111/rda.12834

Source DB:  PubMed          Journal:  Reprod Domest Anim        ISSN: 0936-6768            Impact factor:   2.005


  50 in total

Review 1.  The widespread regulation of microRNA biogenesis, function and decay.

Authors:  Jacek Krol; Inga Loedige; Witold Filipowicz
Journal:  Nat Rev Genet       Date:  2010-07-27       Impact factor: 53.242

2.  Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease.

Authors:  Ryan L Boudreau; Ryan M Spengler; Beverly L Davidson
Journal:  Mol Ther       Date:  2011-09-27       Impact factor: 11.454

3.  Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.

Authors:  Roberto Calcedo; Luk H Vandenberghe; Guangping Gao; Jianping Lin; James M Wilson
Journal:  J Infect Dis       Date:  2009-02-01       Impact factor: 5.226

4.  Applying gene silencing technology to contraception.

Authors:  G A Dissen; A Lomniczi; R L Boudreau; Y H Chen; B L Davidson; S R Ojeda
Journal:  Reprod Domest Anim       Date:  2012-12       Impact factor: 2.005

5.  Regulation of NKB pathways and their roles in the control of Kiss1 neurons in the arcuate nucleus of the male mouse.

Authors:  V M Navarro; M L Gottsch; M Wu; D García-Galiano; S J Hobbs; M A Bosch; L Pinilla; D K Clifton; A Dearth; O K Ronnekleiv; R E Braun; R D Palmiter; M Tena-Sempere; M Alreja; R A Steiner
Journal:  Endocrinology       Date:  2011-09-13       Impact factor: 4.736

Review 6.  The advent of AAV9 expands applications for brain and spinal cord gene delivery.

Authors:  Robert D Dayton; David B Wang; Ronald L Klein
Journal:  Expert Opin Biol Ther       Date:  2012-04-20       Impact factor: 4.388

7.  Mammalian microRNAs predominantly act to decrease target mRNA levels.

Authors:  Huili Guo; Nicholas T Ingolia; Jonathan S Weissman; David P Bartel
Journal:  Nature       Date:  2010-08-12       Impact factor: 49.962

Review 8.  RNA-Seq: a revolutionary tool for transcriptomics.

Authors:  Zhong Wang; Mark Gerstein; Michael Snyder
Journal:  Nat Rev Genet       Date:  2009-01       Impact factor: 53.242

9.  Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle.

Authors:  Aravind Asokan; Julia C Conway; Jana L Phillips; Chengwen Li; Julia Hegge; Rebecca Sinnott; Swati Yadav; Nina DiPrimio; Hyun-Joo Nam; Mavis Agbandje-McKenna; Scott McPhee; Jon Wolff; R Jude Samulski
Journal:  Nat Biotechnol       Date:  2009-12-27       Impact factor: 54.908

10.  Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy.

Authors:  Yong Hong Chen; Michael Chang; Beverly L Davidson
Journal:  Nat Med       Date:  2009-09-13       Impact factor: 53.440

View more
  5 in total

1.  Epigenetic repression of gonadotropin gene expression via a GnRH-mediated DNA delivery system.

Authors:  Lilach Pnueli; Philippa Melamed
Journal:  Gene Ther       Date:  2022-03-17       Impact factor: 5.250

2.  Adeno-associated virus-binding antibodies detected in cats living in the Northeastern United States lack neutralizing activity.

Authors:  Kei Adachi; Gregory A Dissen; Alejandro Lomniczi; Qing Xie; Sergio R Ojeda; Hiroyuki Nakai
Journal:  Sci Rep       Date:  2020-06-22       Impact factor: 4.379

3.  Pre-existing antibodies to candidate gene therapy vectors (adeno-associated vector serotypes) in domestic cats.

Authors:  Pengfei Li; Eva Boenzli; Regina Hofmann-Lehmann; A Katrin Helfer-Hungerbuehler
Journal:  PLoS One       Date:  2019-03-21       Impact factor: 3.240

4.  A TAC3 Missense Variant in a Domestic Shorthair Cat with Testicular Hypoplasia and Persistent Primary Dentition.

Authors:  Petra Hug; Patricia Kern; Vidhya Jagannathan; Tosso Leeb
Journal:  Genes (Basel)       Date:  2019-10-14       Impact factor: 4.096

5.  Adeno-Associated Vector-Delivered CRISPR/SaCas9 System Reduces Feline Leukemia Virus Production In Vitro.

Authors:  A Katrin Helfer-Hungerbuehler; Jimit Shah; Theres Meili; Eva Boenzli; Pengfei Li; Regina Hofmann-Lehmann
Journal:  Viruses       Date:  2021-08-18       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.